Ashling Wahner

Bemarituzumab combined with mFOLFOX6 shows promising overall survival benefits in advanced FGFR2b-overexpressing gastric cancer, despite safety concerns.

New trial data reveals T-DXd significantly improves disease-free survival in high-risk HER2-positive breast cancer patients compared to T-DM1, offering hope for better outcomes.

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for heavily treated patients.

New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with FGF19 overexpression.

A novel bispecific antibody, BNT327/PM8002, shows promising efficacy in treating unresectable mesothelioma, combining well with chemotherapy for durable responses.

Ziftomenib shows promising results in treating relapsed/refractory NPM1-mutant AML, achieving significant remission rates and a favorable safety profile.

In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

Avelumab plus axitinib was effective and safe in real-world advanced kidney cancer, with outcomes matching clinical trials, according to AVION study findings.

UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 Genitourinary Cancers Symposium.

NKTR-255 with CD19 chimeric antigen receptor T-cell therapy improved 6-month complete response rates in relapsed/refractory large B-cell lymphoma.

Zoldonrasib showed preliminary antitumor activity and manageable adverse events in KRAS G12D–mutated PDAC, per phase 1 trial data.

Adding blinatumomab to chemotherapy led to a significant improvement in disease-free survival in pediatric patients with standard-risk pediatric B-ALL.

A new combination therapy involving belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone showed promising results in patients with multiple myeloma who had received 1 prior line of therapy.

Maintenance therapy with daratumumab and lenalidomide led to higher MRD-negative conversion rates compared to lenalidomide alone in newly diagnosed multiple myeloma patients following transplant.

In FRα-positive, platinum-resistant ovarian cancer, mirvetuximab soravtansine showed improvements in progression-free survival, overall response rate, and overall survival.

Imetelstat sustained red blood cell transfusion independence in patients with lower-risk myelodysplastic syndrome, with most responders experiencing durable responses.

Findings from a subgroup analysis of the phase 3 LITESPARK-005 trial showed that belzutifan demonstrated superior efficacy and safety outcomes vs everolimus across prespecified subgroups.

CEE therapy alone in postmenopausal women after hysterectomy was linked to a substantial increase in ovarian cancer incidence and mortality.

Improved outcomes with lutetium Lu 177 vipivotide tetraxetan vs ARPI change supported prior treatment with abiraterone vs enzalutamide in mCRPC.

An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.

Orca-T demonstrated survival rates vs post-transplant cyclophosphamide in patients with hematologic malignancies receiving myeloablative conditioning, according to findings from a retrospective analysis.

The phase 3 AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma successfully achieved its primary end point. However, the interim analysis did not meet the overall survival end point.

The neoadjuvant administration of botensilimab/balstilimab resulted in strong responses in individuals with both resectable mismatch repair–proficient and –deficient colorectal cancer.

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

Use of oral decitabine and cedazuridine vs intravenous/subcutaneous standard-of-care parenteral hypomethylating agents showed similar safety results but also improved treatment in in patients with myelodysplastic syndrome.

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.